NCT03875495 · REGISTRY CONDITION SEARCH

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: TERMINATED
Registry last update: 2022-01-28

This is a non-randomized, open label, phase I/II, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a lentiviral vector driving myeloid-specific interferon-ɑ2 expression, which will be administered to up to 9 patients affected by multiple myeloma in early relapse after intensive front line treatment.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Tolerability and Safety of Temferon Over the First 90 Days Following Administration as Determined by the Incidence of CTCAEs

→

outcome · NOT POSTED

Long Term Tolerability and Safety of Temferon as Determined by the Incidence of CTCAEs

→

outcome · NOT POSTED

Proportion of Patients Achieving Hematologic Recovery by Day +30 (Defined as the First of at Least 3 Consecutive Days With a Neutrophil Count >0.5 x 10^9/L and Platelet Count >20 x 10^9/L) in the Absence of Transfusions

→

outcome · NOT POSTED

Determine the Maximum Tolerated Dose of Temferon

→

outcome · NOT POSTED

Identify Presence of Transduced Myeloid Cells in Bone Marrow as Determined by Vector Copy Number

→

outcome · NOT POSTED

Identify Presence of Transduced Myeloid Cells in Peripheral Blood as Determined by Vector Copy Number

→

outcome · NOT POSTED

Identify Persistence of Transduced Myeloid Cells in Bone Marrow and Peripheral Blood as Determined by Vector Copy Number

→

outcome · NOT POSTED

Determine Clinical Response in Patients as Determined by IMWG Response Criteria

→

outcome · NOT POSTED

Fraction of Patients Achieving Complete Response With Minimal Residual Disease (MRD) Negativity

→

outcome · NOT POSTED

Determine Progression Free Survival in Patients

→

outcome · NOT POSTED

Determine Overall Survival in Patients

→

outcome · NOT POSTED

Changes in Functional Status (Eastern Cooperative Oncology Group, ECOG)

→

outcome · NOT POSTED

Changes in Functional Status (Karnofsky)

→

outcome · NOT POSTED

Changes in Quality of Life: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30

→

outcome · NOT POSTED

Changes in Quality of Life: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-MY20

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Multiple myeloma patients with early relapse after intensive front-line treatment and disease measurable by serum biomarkers, who have obtained at least a VGPR after second-line salvage treatment. * Able and willing to provide written informed consent. * Able to comply with study protocol and procedures. * Performance status scores: Eastern Cooperative Oncology Group (ECOG) \< 2 and Karnofsky \> 70%. * Life expectancy of ≥ 6 months. * Adequate cardiac, renal, hepatic and pulmonary functions as evidenced by (at screening and prior to conditioning): * Left ventricular ejection fraction (LVEF) ≥ 45% by echo and normal electrocardiogram (ECG) or presence of abnormalities not significant for cardiac disease. Absence of severe pulmonary hypertension; * Diffusing capacity of the lung for carbon monoxide (DLCO) \>50% and forced expiratory volume in 1 sec (FEV1) and forced expiratory vital capacity (FVC) \> 60% predicted (if non cooperative: pulse oximetry \> 95 % in room air); * Serum creatinine \< 2x ULN and estimated glomerular filtration rate (eGFR) \> 30 ml/min/1.73m2; * Alkaline phosphatase (ALP), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5 x ULN, and total bilirubin ≤ 2.0 mg/dl. * Women of child-bearing potential enrolled in the study must have a negative pregnancy test at screening and agree to use two distinct acceptable methods of contraception during the trial. * Men enrolled in the study with partners who are women of child bearing potential, must be willing to use an acceptable barrier contraceptive method during the trial or have undergone successful vasectomy at least 6 months prior to entry into the study. Successful vasectomy needs to have been confirmed by semen analysis. Exclusion Criteria: * Use of other investigational agents within 4 weeks prior to experimental treatment (within 6 weeks if use of long-acting agents). * Severe active viral, bacterial, or fungal infection at eligibility evaluation. * Active autoimmune disease or a clinically relevant autoimmune manifestations, requiring immunosuppressive treatment, i.e. psoriasis, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, immune-mediated peripheral neuropathies. * Active sarcoidosis requiring steroid or other immunosuppressive treatment. * Primary amyloidosis. * History of neuropsychiatric illness including severe depression, schizophrenia, bipolar disorders, impaired cognitive function, dementia or suicidal tendency. * Neuropathy \> grade 2. * History of severe cardiovascular disease such as prior stroke, coronary artery disease requiring intervention, unresolved arrhythmias. * Malignant neoplasia (except local skin cancer or cervical intraepithelial neoplasia) or family history of familial cancer syndromes. * Myelodysplasia, cytogenetic or molecular alterations specifically associated with clonal hematopoiesis of the myeloid lineage, or other serious hematological disorder other than the plasma cell dyscrasia. * Other clinical conditions judged by the Investigator non-compatible with the study procedures. * Positivity for HIV-1 or HIV-2 (serology or RNA), and/or Hepatitis B Virus Surface Antigen (HbsAg) and/or Hepatitis B Virus (HBV) DNA and/or Hepatitis C Virus (HCV) RNA (or negative HCV RNA but on antiviral treatment) and/or Treponema Pallidum or Mycoplasma active infection. * Active alcohol or substance abuse within 6 months of the study. * Pregnancy or lactation. * Previous allogeneic bone marrow transplantation, kidney or liver transplant, or gene therapy. * Prior to conditioning: inability to meet the target mobilization cell number needed to manufacture the Drug Product after at least 2 attempts of HSPC collection.
healthy Volunteers: false
maximum Age: 70 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Autologous CD34+-enriched hematopoietic progenitor cells exposed ex vivo to a specific lentiviral vector encoding for the human IFN-ɑ2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of IFN-ɑ2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.
intervention Names
Drug: Temferon
label
Temferon
type
EXPERIMENTAL

interventions

arm Group Labels
Temferon
description
Genetically modified autologous HSPCs
name
Temferon
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 9
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
0 participants analyzed. All the patients were withdrawn before treatment
measure
Tolerability and Safety of Temferon Over the First 90 Days Following Administration as Determined by the Incidence of CTCAEs
time Frame
90 days

secondary Outcomes

description
0 participants analyzed. All the patients were withdrawn before treatment
measure
Long Term Tolerability and Safety of Temferon as Determined by the Incidence of CTCAEs
time Frame
2 years
measure
Proportion of Patients Achieving Hematologic Recovery by Day +30 (Defined as the First of at Least 3 Consecutive Days With a Neutrophil Count >0.5 x 10^9/L and Platelet Count >20 x 10^9/L) in the Absence of Transfusions
time Frame
30 days
measure
Determine the Maximum Tolerated Dose of Temferon
time Frame
30 days
measure
Identify Presence of Transduced Myeloid Cells in Bone Marrow as Determined by Vector Copy Number
time Frame
Up to 2 years
measure
Identify Presence of Transduced Myeloid Cells in Peripheral Blood as Determined by Vector Copy Number
time Frame
Up to 2 years
measure
Identify Persistence of Transduced Myeloid Cells in Bone Marrow and Peripheral Blood as Determined by Vector Copy Number
time Frame
At least 12 weeks
measure
Determine Clinical Response in Patients as Determined by IMWG Response Criteria
time Frame
Up to 2 years
measure
Fraction of Patients Achieving Complete Response With Minimal Residual Disease (MRD) Negativity
time Frame
Up to 2 years
measure
Determine Progression Free Survival in Patients
time Frame
Up to 2 years
measure
Determine Overall Survival in Patients
time Frame
2 years
measure
Changes in Functional Status (Eastern Cooperative Oncology Group, ECOG)
time Frame
2 years
measure
Changes in Functional Status (Karnofsky)
time Frame
2 years

Full study description

brief Summary: This is a non-randomized, open label, phase I/II, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a lentiviral vector driving myeloid-specific interferon-ɑ2 expression, which will be administered to up to 9 patients affected by multiple myeloma in early relapse after intensive front line treatment.
detailed Description: This is a non-randomized, open label, single center, phase I/II, therapeutic exploratory, dose-escalation, prospective study, involving a single intravenous infusion of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor cells (HSPCs) exposed to transduction with a third-generation, vesicular stomatitis virus-G (VSV-G) pseudo-typed lentiviral vector driving myeloid-specific interferon-ɑ2 (IFN-ɑ2) expression, which will be administered to up to 9 patients affected by multiple myeloma in early relapse after intensive front line treatment. The study will recruit, treat and follow-up patients at a specialist hematology and bone marrow transplantation unit at Ospedale San Raffaele (OSR) in Milan, Italy. The study will enrol multiple myeloma patients that have experienced an early relapse after intensive front line treatment, have been treated with an approved second line combination treatment regimen and obtained at least a very good partial remission (VGPR) according to International Myeloma Working Group (IMWG) criteria. Once the written informed consent is obtained, and screening procedures have been completed, harvesting of HSPCs will occur. Patients will be offered maintenance treatment during Temferon production and release. Upon Temferon release for clinical use, patients will be admitted to the transplantation unit for receipt of a reduced-intensity conditioning regimen consisting of melphalan. This will be followed by autologous stem cell transplant (ASCT) and administration of Temferon. In-patient monitoring will occur until hematological recovery occurs. Thereafter, regular follow-up of patients will occur up to 2 years (+730 days). At the +730 day visit, patients will be invited to participate in a long term follow-up study which will last for an additional 6 years. 3 cohorts of 3 patients will receive escalating doses of Temferon. In the event that MM disease progression occurs, patients will be managed according to best clinical practice.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-3ce7ba9af3dee6063754
requested nct id
NCT03875495
primary nct id
NCT03875495
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
1b68d9fbc70a639d72347d34e8857a789279661ececb8815808a1bada7a3caf1
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-3ce7ba9af3dee6063754
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT03875495
occurrences
context exact
NCT03875495
end
11
exact text
NCT03875495
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/67/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
ad17a92f46fa54b6ef51f5731b5a94fdf8a5959803e0e92e124dd3f5df10a33e
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice